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1630Changes of Hepatitis B Virus Serologic Status after
Allogeneic Hematopoietic Stem Cell Transplantation
and Impact of Donor Immunity on Hepatitis B Virus
Silvia Park,1 Kihyun Kim,1 Dong Hwan Kim,1 Jun Ho Jang,1 Seok Jin Kim,1
Won Seog Kim,1 Chul Won Jung,1 Kwang Cheol Koh2Reverse seroconversion (RS) of Hepatitis B virus (HBV) has been reported after allogeneic transplantation
with an incidence of 14% to 86%. However, most prior studies on HBV RS were performed in HBV nonen-
demic areas. In this study, the frequency of HBV RS at a single center in Korea, endemic for HBV, was eval-
uated. Also, the influence of the donor’s immunity for HBVon posttransplantation HBV serologic changes in
recipients was also investigated. A total of 288 patients underwent allogeneic transplantation between Feb-
ruary 1996 and June 2008.We retrospectively reviewed the medical records of 288 patients and their paired
donors. Among the 268 HBsAg(2) patients, 205 were assessed for posttransplantation HBsAg, and 114
(55.6%) of 205 had HBcAb before transplantation.With a median follow-up of 77.9 months, 3 of 114 patients
experienced HBV RS (2.6%). With regard to donor immunity, significantly more patients with anti-HBs(2)
donors experienced anti-HBs loss (P 5 .006), and the donor anti-HBs showed significant protective effects
against the anti-HBs loss with an HR of 0.4. HBV RS after allogeneic transplantation may not be as common in
HBVendemic areas. Also, donor anti-HBs showed a significant favorable effect on maintaining HBV immunity
in recipients.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) accompanied by intensive chemotherapy and
immunosuppression can cause immune dysfunction,
which is associated with infectious complications
including viral infection [1]. Hepatitis B virus (HBV)
infection is 1 of the most common viral infections in
humans. More than 2 billion individuals worldwide
have been exposed to HBV, and more than 350 million
persons are HBsAg carriers, the main reservoir of1Division of Hematology-Oncology, Department of
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6/j.bbmt.2011.04.006hepatitis B in human beings [2]. HBV reactivation
after allogeneic HSCT (allo-HSCT) is a possible com-
plication in patients with HBsAg before transplanta-
tion, and may lead to hepatic complications [3-5]. In
addition, posttransplantation HBV reactivation in
patients with negative HBsAg, but with positive anti-
HBsAb and/or anti-HBcAb before transplantation, re-
ferred to as HBV reverse seroconversion (RS), has also
been reported as a complication of allogeneic
HSCT (allo-HSCT) [6-18]. The reported frequency
of RS varies from 14% to 86% based on a small
number of patients. However, most prior studies on
HBV RS were performed in HBV nonendemic
areas.
There are several data showing that the transfer
of donor immunity by way of allogeneic HSCT
(allo-HSCT) may affect the posttransplantation recip-
ient immunity against HBV [6,7,19-22]. Clearance of
HBsAg after transplantation from immune donors
has been observed in patients with chronic HBV
infection [19,20]. A previous analysis reported no
HBV reactivation occurred among 7 patients with
anti-HBs-positive donors, whereas 4 of 30 patients
without anti-HBs donors experienced HBV RS [6],
and the absence of HBsAb in a donor is reportedly
Biol Blood Marrow Transplant 17:1630-1637, 2011 1631HBV Reactivation after Allogeneic Transplantationa risk factor for HBV RS after HSCT [6,7].
Furthermore, there was a report that the elective
immune transfer by donor vaccine leads to
spontaneous recovery of HBV immunity and the
memory response in recipients [21]. Based on these
results, HBV vaccination of donors was expected to
play a positive role in preventing HBV reactivation
in recipients. By contrast, another study reported no
significant effect of the donor’s vaccinated immunity
on maintenance of positive HBsAb in recipients [23].
In this study, we evaluated serologic changes of
HBV in patients after allogeneic HSCT (allo-
HSCT) and examined the cumulative incidence of
HBVRS at a single center in Korea, where HBV infec-
tion is endemic. In addition, the effect of the donor’s
immunity for HBV on the posttransplantation HBV
serologic status of recipients was examined.PATIENTS AND METHODS
Patients: Recipients and Donors
A total of 289 patients underwent allogeneicHSCT
(allo-HSCT) between February 1996 and June 2008 at
our institution. HCV and HIV serologic markers were
also evaluated in all patients; 1 patient who had HCV
infection before transplantation was excluded from
the analysis. Baseline information on the patients and
complications during the course of the transplantation
were obtained retrospectively from review of the med-
ical records and the bone marrow transplantation
(BMT) database of 288 recipients and their donors.Hepatitis B Markers
All patients were tested for HBV infection before
allogeneic HSCT (allo-HSCT), in accordance with
pretransplantation protocol. HBsAg, anti-HBs, and
anti-HBcwere tested routinely as indicators ofHBV in-
fection. Similarly, all stem cell donors were supposed to
be routinely tested forHBsAg, anti-HBs, and anti-HBc.
However, because of the retrospective nature of this
study, the data collection was not complete. Assessment
of the HBV status was usually performed at 1 year after
transplantation for patients who no longer required im-
munosuppression, after which, the patients without
anti-HBs received HBV vaccination. For the patients
with elevated liver function tests who were suspicious
for hepatitis, the HBV serology was tested earlier than
1 year. Tests were delayed for patients who were under
the immunosuppressive treatment because of chronic
graft-versus-host disease (cGVHD) without signs of
hepatitis. Patients who died before testing could not
be evaluated.
Serum measurements of HBV serology was per-
formed using different assays during the study period.
Measurements of HBsAg, anti-HBs, and anti-HBcwere performed using the ECLIA (electrochemilumi-
nescence immunoassay) or IRMA (immunoradiomet-
ric assay) method. All determinations were assessed
qualitatively except for the anti-HBs, which was mea-
sured by quantitative and/or qualitative IRMA. Al-
though the titer of anti-HBs could be assessed in
some patients, the status of anti-HBs was classified as
either positive or negative, because some of the pa-
tients had no quantitative information available on
their antibody titers.
Definition and Terminology
HBV RS was defined as the appearance of HBsAg
after allo-HSCT in patients who had no HBsAg but
did have anti-HBs or anti-HBc before transplanta-
tion. Transplantation conditioning regimens were
classified into myeloablative (MA) and reduced-
intensity (RIC) based on the conditioning agents
used. During the study period, BuCy (Busulfan and
cyclophophamide), Cy/TBI (cyclophosphamide and
TBI), VCT (etoposide, cyclophosphamide, and TBI),
and Cy/ATG (cyclophosphamide and antithymocyte
globulin) were the MA regimens frequently used,
and Flu/Mel (fludarabine and melphalan) was typi-
cally used as the RIC regimen.
Antiviral Prophylaxis
Antiviral prophylaxis was performed for patients
with positive HBsAg before allo-HSCT using lamivu-
dine. Patients with anti HBc, but not withHBsAg were
not targets of antiviral prophylaxis.
Statistical Analysis
Statistical analysis was performed using the Statis-
tical Package for the Social Sciences (SPSS) v.17.0
(SPSS Inc., Chicago, IL). The cumulative probability
of HBV RS and posttransplant HBsAb disappearance
were calculated by Kaplan-Meier method. Risk factors
for RS and anti-HBs loss were compared by chi-square
or Fisher exact test where appropriate. For identifica-
tion of risk factors that influenced the posttransplant
anti-HBs loss, both univariate and multivariate Cox
proportional hazard model was used, and the hazard
ratio (HR) and 95% confidence interval (CI) were
determined for all of the covariates that were shown
to be statistically significant.RESULTS
Baseline HBV Serologic Status in Recipients and
Donors
The pretransplantation HBV serologic status of
recipients and donors are presented in Tables 1-1
and 1-2. HBsAg and anti-HBs were examined in all
288 patients before transplantation; 20 recipients
Table 1-1. Hepatitis B Markers before HSCT in Recipients
HBsAg Anti-HBs Anti-HBc
No. of
patients (%)
Negative (n 5 268) Positive (n 5 240) Positive 146 (50.7)
Negative 85 (29.5)
Unknown 9 (3.1)
Negative (n 5 28) Positive 2 (0.7)
Negative 23 (8.0)
Unknown 3 (1.0)
Positive (n 5 20) Negative (n 5 20) Positive 18 (6.3)
Unknown 2 (0.7)
1632 Biol Blood Marrow Transplant 17:1630-1637, 2011S. Park et al.were positive for HBsAg and 268 recipients were neg-
ative for HBsAg. Among the 268 patients negative for
HBsAg before transplantation, the proportion of pos-
itive anti-HBs was 89.6% (240 of 268 patients). Of the
268 patients, all but 12 patients were assessed for
antiHBc before allo-HSCT; 148 patients (57.8%)
had anti-HBc, whereas the remaining 108 (42.2%)
patients did not. Among the 288 donors, the number
of cases that had information about the HBsAg status
was 255. Of these 255 donors, 249 were negative for
HBsAg and 6 were positive for HBsAg. Among 249
donors negative for HBsAg before transplantation,
224 cases were assessed for anti-HBs and 213 cases
were assessed for anti-HBc; 132 donors (58.9%) had
anti-HBs and 70 donors (32.9%) were positive for
anti-HBc before transplantation.Pre- and Posttransplantation Characteristics of
HBsAg (2) Recipients
Of the 268 patients who were negative for HBsAg
before transplantation, 205 patients were assessed for
the posttransplantation HBsAg status at least 1 time.
Of these 205 patients, 185 patients had anti HBs
and/or antiHBc before transplantation.With amedian
follow-up period of 77.9 months (range: 21.0-168.4), 3
of 185 patients had HBV RS. Table 2 shows the pre-
and posttransplantation characteristics of the 185 pa-
tients. Statistical analysis was performed to compare
the 2 groups; however, the results were considered to
be of no value, because the number of patients who
experienced HBV RS was only 3. The median age of
the patients at the time of HSCT was 35 (15-64),Table 1-2. Hepatitis B Markers before HSCT in Donors
HBsAg Anti-HBs Anti-HBc
No. of
patients (%)
Negative (n 5 249) Positive (n 5 132) Positive 60 (20.8)
Negative 65 (22.6)
Unknown 7 (2.4)
Negative (n 5 92) Positive 10 (3.5)
Negative 78 (27.1)
Unknown 4 (1.4)
Unknown (n 5 25) Unknown 25 (8.7)
Positive (n 5 6) Negative (n 5 6) Positive 6 (2.1)
Unknown 0 (0)
Unknown (n 5 33) Unknown (n 5 33) Unknown 33 (11.5)and there were more men than women in this patient
group. Acute leukemia was the most common reason
for the allo-HSCT, and myeloablative conditioning
regimens were more frequently used. After excluding
the patients who died within 100 days of transplanta-
tion, information about cGVHD was obtained in 177
patients; 87 patients (49%) had extensive cGVHD.
Among 185 patients, 114 (64%) had anti-HBc before
transplantation. The characteristics of 3 recipients
with HBV-RS are presented in Table 3. All 3 patients
with HBV RS had anti-HBc and anti-HBs before
transplantation. Among the paired donors of these 3
recipients, 2 had complete information about their
HBV serologic status including HBsAg, anti-HBs,
and antiHBc, and both of them were negative for
HBsAg and anti-HBs. The cumulative incidence of
HBV RS was 1.6% among all 185 patients, and 2.6%
among the 114 patients at risk who had resolved
HBV infection before transplantation identified as
positive HBcAb and negative HBsAg. The cumulative
probability of HBV reactivation at 6 years (73 months)
in the at-risk group was 4.8%.HBsAb Loss after allo-HSCTAccording to the
Donor’s Immunity
All 268 patients with negative HBsAg before
transplantation were assessed for pretransplantation
HBsAb, and among them, 203 patients had their
post-anti-HBs status determined after allo-HSCT, at
least 1 time. Of these 203 patients, 181 had anti-HBs
before allo-HSCT. The patients were classified by
their pretransplantation anti-HBs status and further
sorted by their posttransplantation anti-HBs status.
Table 4 shows the pre- and posttransplantation
changes in the anti-HBs in 181 patients who had pos-
itive anti-HBs before transplantation. After a median
follow-up period of 76.3 months (range: 21-168),
125 patients maintained their immunity for HBV,
whereas 56 patients lost their immunity. The cumula-
tive probability of loss of anti-HBs at 6 years after
transplantation was 49.6%. There was no difference
in the loss or maintenance of the anti-HBs based on
pretransplantation characteristics including age, sex,
reason for transplantation, conditioning regimen,
donor relatedness, and stem cell source. The develop-
ment of extensive cGVHD was assessed in 174 of 181
patients; the presence of extensive cGVHD showed
a statistically significant difference between the 2
groups (P 5 .04). The pretransplantation anti-HBc
in recipients was also assessed; there was no difference
in the loss of HBsAb based on pretransplantation anti-
HBc in recipients. In addition, the influence of the
donors’ HBV serologic status on the change in the cu-
mulative incidence of posttransplantation anti-HBs
was evaluated. There was no difference in the inci-
dence of anti-HBs loss according to the donor’s
Table 2. Pre- and Posttransplantation Characteristics of HBsAg(2) Patients before Transplantation
No Reactivation, n 5 182 Reactivation, n 5 3 Total, n 5 185 P value
Median age (range) 35 (16-64) 41 (15-53) 35 (15-64) .798
Sex (M vs F) 100 (55%)/82(45%) 1 (33%)/2 (67%) 101 (55%)/84 (45%) .591
Reason for transplantation
AL or MDS 125 (69%) 1 (33%) 126 (68%)
CL 24 (13%) 1 (33%) 25 (14%)
AA 19 (10%) 1 (33%) 20 (11%)
Others 14 (8%) 0 (0%) 14 (8%) .239
Conditioning regimen
MA 172 (95%) 3 (100%) 175 (95%)
RIC 10 (6%) 0 (0%) 10 (5%) 1.000
Donor relatedness
Sibling 115 (63%) 1 (33%) 116 (63%)
Unrelated 67 (37%) 2 (67%) 69 (37%) .557
Stem cell source
BM 95 (52%) 2 (67%) 97 (52%)
PB 84 (46%) 1 (33%) 85 (46%)
CB 3 (2%) 0 (0%) 3 (2%) 1.000
Extensive cGVHD
Death within 100 days 8 0 8
Survival after 100 days total, n 5 174 total, n 5 3 total, n 5 177
Extensive cGVHD (+) 85 (49%) 1 (33%) 87 (49%)
Extensive cGVHD (2) 89 (51%) 2 (67%) 90 (51%) .617
Recipient HBV serologic markers before transplantation
HBsAb
(+) 180 (99%) 3 (100%) 183 (99%)
(2) 2 (1%) 0 (0%) 2 (1%) 1.000
HBcAb
Unavailable 8 0 8
Available total, n 5 174 total, n 5 3 total, n 5 177
(+) 111 (64%) 3 (100%) 114 (64%)
(2) 63 (36%) 0 (0%) 63 (36%) .553
Donor HBV serologic markers before transplantation
HBsAg
Unavailable 14 0 14
Available total, n 5 168 total, n 5 3 total, n 5 171
(+) 1 (1%) 0 (0%) 1 (1%)
(2) 167 (99%) 3 (100%) 169 (99%) 1.000
HBsAb
Unavailable 31 1 32
Available total, n 5 151 total, n 5 2 total, n 5 153
(+) 90 (60%) 0 (0%) 90 (59%)
(2) 61 (40%) 2 (100%) 63 (41%) .168
HBcAb
Unavailable 41 1 42
Available total, n 5 141 total, n 5 2 total, n 5 143
(+) 47 (33%) 1 (50%) 48 (34%)
(2) 94 (67%) 1 (50%) 95 (66%) 1.000
BM indicates bone marrow; PB, peripheral blood; CB, cord blood; cGVHD, chronic graft-versus-host disease; MDS, myelodysplastic syndrome; AL,
Acute leukemia; CL, Chronic leukemia; AA, aplastic anemia; MA, myeloablative.
Biol Blood Marrow Transplant 17:1630-1637, 2011 1633HBV Reactivation after Allogeneic TransplantationHBcAb status; however, significantly more patients
with nonimmunized donors (donors without anti-
HBs) experienced anti-HBs loss compared with recip-
ients with donors who had anti-HBs.
To determine risk factors associated with the loss
of anti-HBs after allo-HSCT, Cox proportional haz-
ard model was used. A total of 129 patients were finally
included in this analysis, after excluding 52 patients
who had insufficient data for inclusion in the study
such as death before evaluation of cGVHD or insuffi-
cient HBV serology. Both univariate and multivariate
analyses were performed, and the results are listed in
Table 5. Extensive cGVHD and donor anti-HBsAb
retained their significance by both analyses. Patients
who experienced extensive cGVHD had an adjusted
HR 3.0 (P 5 .004) compared with the patient whodid not. In addition, the donor anti-HBs showed sig-
nificant protective effect against the loss of anti-HBs
with an HR of 0.4 (P 5 .011).HBsAb Acquisition after allo-HSCTAccording
to the Donor’s Immunity
Of the above-mentioned 203 patients assessed for
their posttransplantation anti-HBs status, 22 patients
did not have anti-HBs before the allo-HSCT. Among
these 22 patients, 4 patients did not have information
about donor immunity, and 2 patients received vacci-
nations before the first evaluation of anti-HBs during
the posttransplantation period. The remaining 16 pa-
tients included 9 patients with donors who had no
anti-HBs and 7 patients with donors who had anti-
Table 3. Characteristics of 3 Recipients with HBV RS
HBV Serology of Recipient HBV Serology of Donor
Case No.
Pre-HSCT
Anti-HBc
Pre-HSCT
Anti-HBs
Timing of RS
(Month after
HSCT)
Anti-HBs
Status at the
Time of RS
HBeAg Status
at HBV
Diagnosis
Anti-HBe Status
at HBV
Diagnosis
PCR Titer at
HBV Diagnosis
(pg/mL)
Pre-HSCT
HBsAg
Pre-HSCT
Anti-HBc
Pre-HSCT
Anti-HBs
1 (+) (+) 20.8 (2) (+) (2) 1592 (2) unknown unknown
2 (+) (+) 72.8 (2) unknown unknown unknown (2) (+) (2)
3 (+) (+) 27.9 (2) (+) (2) >2266.0 (2) (2) (2)
HSCT indicates hematopoietic stem cell transplanation; HPV RS, hepatitis B reverse seroconversion.
1634 Biol Blood Marrow Transplant 17:1630-1637, 2011S. Park et al.HBs. After the allo-HSCT, 8 of 16 patients newly
gained HBV immunity represented by the presence
of anti-HBs; 3 of 9 patients (33.3%) with nonimmu-
nized donors; and 5 of 7 patients (71.4%) with immu-
nized donors. With regard to the donor anti-HBc,
6 of 12 patients (50%) with donors who had no anti-
HBc and 2 of 4 (50%) patients who received transplan-
tation from donors with anti-HBc newly obtained
anti-HBs.Table 4. HBsAb Disappearance after allo-HSCT in Patients with P
HBsAb (+) $ (2
Average age 35
Sex (M/F) 31 (55%)/25 (
Reason for transplantation
AL or MDS 38 (68%)
CL 5 (9%)
AA 10 (18%)
Others 3 (5%)
Conditioning regimen
MA 52 (93%)
RIC 4 (7%)
Donor relatedness
Sibling 37 (66%)
Unrelated 18 (32%)
Others 1 (2%)
Stem cell source
BM 31 (55%)
PB 18 (32%)
CB 1 (2%)
Extensive cGVHD
Death within 100 days 0
Survival after 100 days Total, n 5
Extensive cGVHD (+) 34 (61%)
Extensive cGVHD (2) 22 (39%)
Recipient HBV serologic markers before transplantation
HBcAb
Unavailable 1
Available Total, n 5
(+) 34 (62%)
(2) 21 (38%)
Donor HBV serologic markers before transplantation
HBsAb
Unavailable 9
Available Total, n 5
(+) 20 (43%)
(2) 27 (57%)
HBcAb
Unavailable 11
Available Total, n 5
(+) 16 (36%)
(2) 29 (64%)
BM indicates bone marrow; PB, peripheral blood; CB, cord blood; cGVHD, c
reduced intensity conditioning; MA, myeloablative; AL, Acute leukemia; AA, ADISCUSSION
This retrospective study evaluated HBV RS in
a large patient group in a country where HBV infection
is endemic. During a median follow-up period of 77.9
months, the cumulative incidence of HBV RS was
1.6% (3 of 185) among the patients who had anti-HBs
and/or anti-HBc before transplantation, and 2.6% (3
of 114) among the patients at risk who had resolved
HBV infection before transplantation identified asretransplant Anti-HBs
), n 5 56 HBsAb (+) $ (+), n 5 125 P value, total, n 5 181
36 .485
45%) 67 (54%)/58 (46%) .826
87 (70%)
17 (14%)
10 (8%)
11 (9%) .195
119 (95%)
6 (5%) .502
71 (57%)
46 (37%)
8 (6%) .294
63 (50%)
61 (49%)
1 (1%) .666
7 7
56 Total, n 5 118 Total, n 5 174
52 (44%)
66 (56%) .04
7 8
55 Total, n 5 118 Total, n 5 173
77 (65%)
41 (35%) .661
21 30
47 Total, n 5 104 Total, n 5 151
69 (66%)
35 (34%) .006
29 40
45 Total, n 5 96 Total, n 5 141
32 (33%)
64 (67%) .795
hronic graft-versus-host disease; MDS, myelodysplastic syndrome; RIC,
plastic anemia.
Table 5. Risk Factors for Posttransplant Loss of Anti-HBs
Univariate Analysis Multivariate Analysis
P value HR (95% CI) P value
HR
(95% CI)
Age .338 * .516 *
Sex
Male .322 * .451 *
Female
Reason for transplantation
AL or MDS .122 * .138 *
CL
AA
Others
Conditioning regimen
MA .055 * .146 *
RIC
Donor relatedness
Sibling .647 * .35 *
Unrelated
Stem cell source
BM .017 2.249 (1.155-4.383) .887 *
PB
Extensive cGVGD
(2) .002 2.712 (1.431-5.139) .004 2.999
(1.407-6.395)(+)
Recipient HBcAb
(2) .036 0.508 (0.270-0.957) .078 *
(+)
Donor HBsAb
(2) .002 0.396 (0.218-0.720) .011 0.388
(0.187-0.806)(+)
Donor HBcAb
(2) .333 * .082 *
(+)
BM indicates bonemarrow; PB, peripheral blood; cGVHD, chronic graft-
versus-host disease; MDS, myelodysplastic syndrome; HR, hazard ratio;
CI, confidence interval; RIC, reduced-intensity conditioning; MA,
myeloablative; CL, Chronic leukemia; AA, Aplastic anemia; AL, Acute
leukemia.
Biol Blood Marrow Transplant 17:1630-1637, 2011 1635HBV Reactivation after Allogeneic Transplantationpositive HBcAb and negative HBsAg. In addition, the
cumulative probability at 6 years after transplantation
was 3.7% among the patients with resolved HBV infec-
tion. RS of HBV has been reported as a late complica-
tion of HSCT. The incidence of HBV RS based on
the findings of a number of studies has varied from
14% to 86%. According to the results of a recent large
study, the cumulative probability at 4 years after allo-
HSCTwas 43% [24]. Compared with previous reports,
the frequency and probability of HBV RS in this study
was significantly lower (Table 6).
Korea is a country with endemic HBV infection.
According to the National Health and Nutrition Sur-
vey of 1998 [25], HBsAg seropositivity in Korea wasTable 6. Rate of HBV RS in Comparison with Other Literatures
References Rate of HBV RS
Dhedin et al., Transplantation 1998 20.5% (4 of 37)
Seth et al., Bone Marrow Transplant. 2002 14% (6 of 42)
Knoll et al., Bone Marrow Transplant. 2004 50% (3 of 6)
Onozawa et al., Transplantation 2005 50% (7 of 14)
Knoll et al., J Viral Hepatol. 2007 85.7% (6 of 7)
Sarah et al., Blood Marrow Transplant. 2009 19.7% (12 of 61)
HBV RS indicates hepititis B reverse seroconversion; F/U, follow-up.present in 5.1% of men and 4.1% of women. Although
the prevalence of HBsAg has been decreasing since the
1980s, because of the availability of vaccinations, Korea
remains an area endemic for HBV. This was reflected
in the patient group of this study. Among all patients,
HBsAg seropositivity was present in 6.9%, and
57.8%of the patients had evidence of resolvedHBV in-
fection before transplantation. However, the propor-
tion of patients with a history of resolved HBV
infection was only 4.4% in a study conducted in the
United States [24]. Given that the incidence of HBV
RS in a study conducted in the United States was
19.7%, the incidence of HBV RS present in this study
was very low: only 2.6% among the patients at risk.
These findings illustrate the different epidemiology
for HBV infection between endemic and nonendemic
regions, and consequently, suggest to us that the data
from nonendemic regions might significantly differ
from the data collected in endemic regions. In addition,
it seems that HBV reactivation after allo-HSCT is
a less common complication in HBV endemic areas.
With regard to the clinical characteristics of the
patients before and after transplantation, there was
no significant difference between the findings from
this institution and the findings from other institutions
previously reported. We do not know exactly where
the difference originated. There may have been some
differences in treatment protocols among the different
centers. For example, during the posttransplantation
follow-up period, immediate vaccination of recipients
is performed at this center at the time when the pa-
tients are recognized to have no immunity for HBV.
In addition, it could be possible to think that the differ-
ence is partly because different regions likely have dif-
ferent rates of immunity for HBV. To generalize and
confirm the low incidence of HBV RS in the endemic
area, the first thing to check is the incidence of reverse
seroconversion in other institutions in Korea as well as
institutions in other endemic areas for HBV such as
China and other parts of Asia, except Japan where
prevalence of HBV surface antigen is relatively low.
The important thing we have to notice is that the vac-
cination has been mandatorily recommended since the
1980s in Korea, and active HBV prophylaxis targeting
newborns with HBsAg(1) parents are conducted
now. After 5 to 10 years, it will be helpful to reevaluate
HBV RS aimed at patients of the postvaccination eraMedian F/U Period Nationality
20 months France
16 months Saudi Arabia
30 months Germany
48 months Japan
53 months Germany
17 months USA
1636 Biol Blood Marrow Transplant 17:1630-1637, 2011S. Park et al.with the understanding that the change in epidemiol-
ogy of HBV infection can influence the rate of HBV
RS. However, the reason why HBV reactivation after
allo-HSCT in the endemic area was quite low
remains unclear.
Other HBV serologic changes, such as the loss of
anti-HBs, have been reported as well as HBV RS
[10,23]. Although it seems that recipient-derived
humoral immunity would have a protective effect
against HBV reactivation after allo-HSCT [24], it has
been suggested that the loss of previous HBV
immunity might be inevitable as a result of the gradual
loss of the recipient’s immune cells in combinationwith
the prolonged inadequate T cell-dependent B cell
responses [26,27]. Similarly, several groups have
reported a tendency for thedecline in the anti-HBs level
after transplantation, which may be associated with the
increased susceptibility to HBV reactivation [10,28].
The 3 patients in this study who experienced HBV RS
also had loss of anti-HBs when they were identified as
having HBV reactivation. These findings emphasize
the importance of the maintenance of HBV immunity
for the prevention of HBV reactivation.
However, the information on anti-HBs loss after
transplantation is limited, and is usually derived from
studies with a small number of patients and with
short-term follow-up [6,7,9,10,29]. In 2007, a Greek
group reported on HBsAb loss during the
posttransplantation period in a large cohort of 82
patients [23]. They reported that the probability of
HBsAb loss was as high as 90% at 5 years. In addition,
they attempted to identify risk factors that affected
anti-HBs loss, and the marrow graft, ATG administra-
tion, age\30 years, and cGVHD were emphasized as
significant predictive factors. With regard to donor
immunity, they reported that the presence of donor
immunity did not significantly influence HBsAb
negativity in their patient group. In this study, the
risk factors for anti-HBs loss after transplantation
were also evaluated. The findings showed that donor
immunity for HBV had a protective effect against the
loss of anti-HBs in the recipients. When compared
by the Fisher exact test and analyzed by the Cox pro-
portional hazard model, the donors’ anti-HBs contin-
ued to be a statistically significant factor. These
findings are not consistent with those of the Greek
study discussed above. One possible explanation for
this discrepancy is the small sample size of the Greek
study compared with the size of this study and the dif-
ferent method of categorization of donor immunity. In
addition to the donors’ anti-HBs status, the presence
of extensive cGVHD was identified as a significant
risk factor for posttransplantation anti-HBs loss by
both univariate and multivariate analyses. It is very in-
teresting that the presence of extensive cGVHD has
also been designated as a risk factor for HBV RS in
a previous report [24].With regard to vaccination, donor vaccination
has been shown to improve the posttransplantation
immunity of the recipient in the case of tetanus toxoid,
7-valent pneumococcal conjugate vaccine (PCV),
and Haemophilus influenza type b-conjugate vaccines
[30]. However, with regard to HBV, the efficacy of do-
nor vaccination has not been well established; this issue
continues to be debated [5,6,12,17,31,32]. In this study,
there was a protective effect of the donors’ anti-HBs on
the maintenance of the recipients’ immunity for HBV;
therefore, the recommendation for HBV vaccination
in donors seems to be reasonable. Also, it may be per-
haps that the effect of donor vaccination can be notably
seen in HBV nonendemic areas where the rate of HBV
RS among the patients at risk is relatively high.
The limitations of this study include the following.
First, a quantitative assessment of the anti-HBs titer
was not performed in all patients; therefore, it was
impossible to determine the serial changes of the
anti-HBs precisely. Second, the posttransplantation
serum measurement of the HBV serology was not
standardized. Therefore, the timing of the first exam-
ination after transplantation and the interval between
each examination was varied. Third, it would be help-
ful in understanding a protective effect of donor im-
munity against HBV RS, especially in regard to type
of donor immunity, if the information about prior im-
munization was included in this analysis. Unfortu-
nately, we did not know the patients’ or donors’
histories if they were vaccinated for HBV or not before
allo-HSCT. Indirectly, patients or donors with anti-
HBs(1)/anti-HBc(1), or with anti-HBs(2)/anti-
HBc(1), were supposed to have been exposed to
previous HBV infection. In case of anti-HBs(1)/
anti-HBc(2), however, there may be a mixture of pa-
tients or donors who had immunity for HBV because
of vaccination and individuals with uncomfirmed
anti-HBc despite of exposure to previous HBV infec-
tion. Because of the uncertainty for source of immu-
nity, we could not identify the benefits of transfer of
donor immunity based on type of immunization.
In summary, HBV RS is a well-known late compli-
cation of allo-HSCT reported to occur in more than
10% of cases. However, the incidence of HBV RS in
this study, which was performed at a single center in
Korea where HBV is endemic, was only 2.6% among
patients with anti-HBc before transplantation. This
suggests that HBV RS after allo-HSCT may not be as
common in HBV endemic areas, and that the incidence
of HBV RS likely differs depending on the epidemiol-
ogy for HBV infection in a given region. With regard
to posttransplantation anti-HBs loss, the donor anti-
HBs had a significant favorable effect on maintaining
the HBV immunity of recipients with anti-HBs before
transplantation. These results should serve as a basis
for future studies and for developing guidelines for
preventing posttransplantation HBV reactivation.
Biol Blood Marrow Transplant 17:1630-1637, 2011 1637HBV Reactivation after Allogeneic TransplantationAUTHORSHIP STATEMENT
Contribution: K.H. Kim andC.W. Jung conceived
the idea and designed research. S. Park collected,
analyzed data, and wrote the manuscript. D.H. Kim,
J.H. Jang, S.J. Kim, W.S. Kim, and K.C. Koh contrib-
uted with the provision of study material or patients.ACKNOWLEDGMENT
Financial disclosure: The authors declare no com-
peting financial interests.REFERENCES
1. Leather HL, Wingard JR. Infections following hematopoietic
stem cell transplantation. Infect Dis Clin North Am. 2001;15:
483-520.
2. EASL International Consensus Conference on Hepatitis B. Sep-
tember 13-14, 2002: Geneva, Switzerland. Consensus statement
(short version). J Hepatol. 2003;38:533-540.
3. Senecal D, Pichon E, Dubois F, Delain M, Linassier C,
Colombat P. Acute hepatitis B after autologous stem cell
transplantation in a man previously infected by hepatitis B virus.
Bone Marrow Transplant. 1999;24:1243-1244.
4. Ma SY, Lau GK, Cheng VC, Liang R. Hepatitis B reactivation
in patients positive for hepatitis B surface antigen undergoing
autologous hematopoietic cell transplantation. Leuk Lymphoma.
2003;44:1281-1285.
5. Iwai K, TashimaM, Itoh M, et al. Fulminant hepatitis B follow-
ing bone marrow transplantation in an HBsAg-negative,
HBsAb-positive recipient; reactivation of dormant virus during
the immunosuppressive period. Bone Marrow Transplant. 2000;
25:105-108.
6. Dhedin N, Douvin C, Kuentz M, et al. Reverse seroconversion
of hepatitis B after allogeneic bone marrow transplantation:
a retrospective study of 37 patients with pretransplant anti-HBs
and anti-HBc. Transplantation. 1998;66:616-619.
7. Goyama S, Kanda Y, Nannya Y, et al. Reverse seroconversion of
hepatitis B virus after hematopoietic stem cell transplantation.
Leuk Lymphoma. 2002;43:2159-2163.
8. Seth P, Alrajhi AA, Kagevi I, et al. Hepatitis B virus reactivation
with clinical flare in allogeneic stem cell transplants with chronic
graft-versus-host disease. Bone Marrow Transplant. 2002;30:
189-194.
9. Knoll A, Boehm S, Hahn J, Holler E, JilgW. Reactivation of re-
solved hepatitis B virus infection after allogeneic haematopoietic
stem cell transplantation. Bone Marrow Transplant. 2004;33:
925-929.
10. Onozawa M, Hashino S, Izumiyama K, et al. Progressive disap-
pearance of anti-hepatitis B surface antigen antibody and reverse
seroconversion after allogeneic hematopoietic stem cell trans-
plantation in patients with previous hepatitis B virus infection.
Transplantation. 2005;79:616-619.
11. Francisci D, Aversa F, Coricelli V, et al. Prevalence, incidence
and clinical outcome of hepatitis B virus and hepatitis C virus
hepatitis in patients undergoing allogeneic hematopoietic stem
cell transplantation between 2001 and 2004. Haematologica.
2006;91:980-982.
12. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term
surveillance of haematopoietic stem cell recipients with resolved
hepatitis B: high risk of viral reactivation even in a recipient with
a vaccinated donor. J Viral Hepatol. 2007;14:478-483.
13. Lau GK, Liang R, Chiu EK, Lee CK, Lam SK. Hepatic events
after bone marrow transplantation in patients with hepatitis Binfection: a case controlled study. Bone Marrow Transplant.
1997;19:795-799.
14. Hui CK, Lie A, Au WY, et al. A long-term follow-up study on
hepatitis B surface antigen-positive patients undergoing
allogeneic hematopoietic stem cell transplantation. Blood.
2005;106:464-469.
15. Ustun C, Koc H, Karayalcin S, et al. Hepatitis B virus infection
in allogeneic bone marrow transplantation. Bone Marrow
Transplant. 1997;20:289-296.
16. Martin BA, Rowe JM, Kouides PA, DiPersio JF. Hepatitis B
reactivation following allogeneic bone marrow transplantation:
case report and review of the literature. Bone Marrow Transplant.
1995;15:145-148.
17. SakamakiH,SatoY,MoriSI, et al.HepatitisBvirus reactivation in
a patient with chronic GVHD after allogeneic peripheral blood
stem cell transplantation. Int J Hematol. 2001;74:342-346.
18. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B
infection following allogeneic bone marrow transplantation in
a hepatitis B-immune patient: case report and review of the
literature. Clin Infect Dis. 2005;41:1277-1282.
19. Lau GK, Lok AS, Liang RH, et al. Clearance of hepatitis B
surface antigen after bone marrow transplantation: role of
adoptive immunity transfer. Hepatology. 1997;25:1497-1501.
20. LauGK, Suri D, Liang R, et al. Resolution of chronic hepatitis B
and anti-HBs seroconversion in humans by adoptive transfer of
immunity to hepatitis B core antigen.Gastroenterology. 2002;122:
614-624.
21. LindemannM, BarsegianV, RundeV, et al. Transfer of humoral
and cellular hepatitis B immunity by allogeneic hematopoietic
cell transplantation. Transplantation. 2003;75:833-838.
22. Idilman R, Ustun C, Karayalcin S, et al. Hepatitis B virus
vaccinationof recipients anddonorsof allogeneicperipheral blood
stem cell transplantation. Clin Transplant. 2003;17:438-443.
23. Kaloyannidis P, Batsis I, Yannaki E, et al. Allografted recipients
immunized against hepatitis B virus are at high risk of gradual
surface antibody (HbsAb) disappearance post transplant, regard-
less of adoptive immunity transfer. Biol Blood Marrow Transplant.
2007;13:1049-1056.
24. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR,
Marty FM. Hepatitis B virus reactivation following allogeneic
hematopoietic stem cell transplantation. Biol Blood Marrow
Transplant. 2009;15:1049-1059.
25. Lee DH, Kim JH, Nam JJ, KimHR, Shin HR. Epidemiological
findings of hepatitis B infection based on 1998 National Health
and Nutrition Survey in Korea. J Korean Med Sci. 2002;17:
457-462.
26. Auletta JJ, Lazarus HM. Immune restoration following
hematopoietic stem cell transplantation: an evolving target.
Bone Marrow Transplant. 2005;35:835-857.
27. Crooks GM, Weinberg K, Mackall C. Immune reconstitution:
from stem cells to lymphocytes. Biol Blood Marrow Transplant.
2006;12:42-46.
28. Onozawa M, Hashino S, Darmanin S, et al. HB vaccination in
the prevention of viral reactivation in allogeneic hematopoietic
stem cell transplantation recipients with previous HBV infec-
tion. Biol Blood Marrow Transplant. 2008;14:1226-1230.
29. Chen PM, Fan S, Liu CJ, et al. Changing of hepatitis B virus
markers in patients with bone marrow transplantation.
Transplantation. 1990;49:708-713.
30. Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of
hematopoietic cell transplant recipients. Bone Marrow Trans-
plant. 2009;44:521-526.
31. Nordbo SA, Skaug K, Holter E, Waage A, Brinch L. Reactiva-
tion of hepatitis B virus infection in an anti-HBc and anti-HBs
positive patient after allogeneic bone marrow transplantation.
Eur J Haematol. 2000;65:86-87.
32. LjungmanP, Lewensohn-Fuchs I,HammarstromV, et al. Long-
term immunity to measles, mumps, and rubella after allogeneic
bone marrow transplantation. Blood. 1994;84:657-663.
